IMAPAC
IMAGINE YOUR IMPACT

EVENT BROCHURE

VACCINE WORLD ASIA CONGRESS 2026 South East Asia

BIOLOGICS WORLD SOUTH EAST ASIA 2026

Southeast Asia's Only Co-Located Vaccine & Biologics Congress

14 - 15 October 2026 Sheraton Grand Jakarta Gandaria City Hotel, Indonesia

OFFICIAL EVENT BROCHURE

https://infohub.imapac.com/vwsea-bwsea-2026-brochure

Table of Contents

About the Event 3
Sponsors & Media Partners 4
2026 Speakers 5
Agenda At A Glance 9
Agenda 10
Expected Audience Snapshot 30
Exhibition Floorplan 31
Who Should Sponsor? 33
Why Sponsor This Event? 33
Our Past Partners 34
Add to Calendar 35
Registration Form 36
About IMAPAC 37

EVENT CONTACTS

HEAD OF PRODUCTION
Lara Santiago
lara.santiago@imapac.com
+639176210686

CONFERENCE PRODUCER
Anusha Shirshyad
anusha.shirshyad@imapac.com
+6569645109

PORTFOLIO SPECIALIST
Caterin Sanggita
caterin.sanggita@imapac.com
+6569836137|+62811654788

BUSINESS DEVELOPMENT MANAGER
Nathan Grace Niño
nathan.grace@imapac.com
+6569836134

EVENT HIGHLIGHTS

300+	130+	60+
ATTENDEES	COMPANIES	SPEAKERS

DATE & VENUE

14 - 15 October 2026

Sheraton Grand Jakarta Gandaria City Hotel
Indonesia

About the Event

Vaccine World Asia Congress – Southeast Asia and Biologics World Southeast Asia return in 2026 as a single co-located platform, uniting Southeast Asia's vaccine and therapeutic-biologics communities under one roof in Jakarta. Together they convene policymakers, manufacturers, researchers, CDMOs, regulators, investors and technology partners driving the region's fastest-growing areas of biopharma.

The Vaccine Congress spotlights infectious-disease immunisation, next-generation platforms (mRNA, recombinant, viral vectors, thermostable formulations) and the drive toward regional vaccine self-sufficiency, while Biologics World Southeast Asia focuses on the full therapeutic-biologics value chain — monoclonal antibodies, biosimilars, ADCs and protein therapeutics, from R&D and translational science through bioprocessing, manufacturing scale-up and market access. Co-locating the two enables cross-industry exchange across the broader biopharmaceutical ecosystem while preserving each event's distinct scientific and commercial agenda — positioning ASEAN as a competitive hub for both vaccines and biologics.

Sponsors & Media Partners

GOLD

BD

BRONZE

Schrödinger

EXHIBITORS

DOU YEE ENTERPRISES

cytiva

Waters | TA Instruments

Haier Biomedical
Intelligent Protection of Life Science

Pfanstiehl

Biomed Global

Air Dynamics

ASSOCIATE

OPTIMA

MARKEN
UPS Healthcare Precision Logistics

Tofflon

INMARK LIFE SCIENCE

Regenic
Cell Therapy | New Hope New Life

Business Development Manager:
Nathan Grace Niño · nathan.grace@imapac.com · +6569836134

2026 SPEAKERS

VACCINE WORLD ASIA CONGRESS 2026 SOUTH EAST ASIA



Ms Wenny Indriasari
Director of Pharmaceutical and Medical Device Resilience
Ministry of Health
INDONESIA



Badarulhisam Abdul Rahman, PhD
Chief Scientific Officer
Pharmaniaga Berhad
MALAYSIA



Zainab Sadat
General Manager, Vaccines, Southeast Asia & India MCO
Sanofi
SINGAPORE



Meenu Batolar
Global Regulatory Affairs Asia Pacific Lead
CEPI
SINGAPORE



Dr. Neni Nurainy
Head of Translational Development of Life Science Product
Bio Farma
INDONESIA



M. Indra Lamora
Director – Anti Infectious Department
Etana Biotechnologies
INDONESIA



Indriana Permatasari
Project Manager
International Vaccine Institute (IVI)
INDONESIA



Dr. Soleh Ayubi
Chief of Country Representative
PATH
INDONESIA



Dr. Jetsumon Sattabongkot Prachumsri
Global Talent Researcher
Mahidol University
THAILAND



Dr. Indra Rudiansyah
Project Lead, mRNA Vaccine Programme
Bio Farma
INDONESIA



Dr. Wenshuo Zhou
Senior Director R&D & CEO Scientific Assistant
Abogen Biosciences
CHINA



Prasen Adya
Deputy Director
Serum Institute of India
INDIA



Dr. Nicholas Lim
Medical Head, RSV Vaccines India & Southeast Asia MCO
Sanofi
SINGAPORE



Dr. Seyed Reza Banihashemi
Director of R&D
Razi Vaccine & Serum Research Institute
IRAN



Xiaoyuan Zhao
International Clinical Project Management Expert, R&D Division
CanSino Biologics Inc.
SWITZERLAND



Mr. Mohd Fadhil bin Razmi
Head of Cluster, Vaccine & Logistics, Malaysia Vaccine Project Office (MVPO)
Ministry of Science, Technology & Innovation (MOSTI)
MALAYSIA

VACCINE WORLD ASIA CONGRESS 2026 SOUTH EAST ASIA



Claire Chong
Technical application manager
Tofflon Science and Technology Group Co., Ltd.
SINGAPORE



Sophie Lam
Regional Business Manager
BD Southeast Asia Biopharma System
SINGAPORE



Yuli Fitriyani Syoemantri
Head of BCG Vaccine Production Department
Bio Farma
INDONESIA



Dr. Martina Ochs
Programme Leader - RNA Programme
CEPI
UNITED KINGDOM



Dr. Mrunal Shetye
Chief of Health
UNICEF Indonesia Country Office

BIOLOGICS WORLD ASIA CONGRESS 2026 SOUTH EAST ASIA



Abhijit Kayal
Senior Scientist II
Schrodinger
INDIA



Sophie Lam
Regional Business Manager
BD Southeast Asia Biopharma System
SINGAPORE



Bobby George
Senior Vice President, Head Regulatory Affairs
Reliance Life Sciences
INDIA



Butet Manurung
Managing Director
Jakarta Biopharmaceutical Industry (JBio)
INDONESIA



Cheng Yi (Jerry) Kuo
Vice General Manager
UWELL Biopharma
TAIWAN



Chethan A J
Assistant Director - QA & RA, Center for Ocular Regeneration (CORE)
Brien Holden Eye Research Center (BHERC)
INDIA



Christian Karol Saputra
Head of Corporate Relation & Strategic Affair
Etana Biotechnologies
INDONESIA



Deepak Mukherjee
Country Medical Director
Roche
INDONESIA



Doo Young Jung
Chief Executive Officer
PinotBio
SOUTH KOREA



Kurt Wee
Chief Executive Officer
Celligenics
SINGAPORE



Lutfhi Zarkasyi
Director of Manufacturing
Kalbio Global Medika
INDONESIA



Nicolas Husser
Head of Operations
Kalbio Global Medika
INDONESIA



Rakhmat Budi Yuwono
Quality Director
Etana Biotechnologies
INDONESIA



Dr. Seyed Reza Banihashemi
Director of R&D
Razi Vaccine & Serum Research Institute
IRAN



Sandy Qlintang
President Director
Bifarma Adiluhung
INDONESIA



Shanti Marlina Sibuea
Acting Director of Production Control of Drugs, Narcotics, Psychotropics, and Precursors
Indonesian National Agency of Drug and Food Control (Badan POM/BPOM)
INDONESIA

BIOLOGICS WORLD ASIA CONGRESS 2026 SOUTH EAST ASIA



Syifa Mutiara Hersista
Digital Tech Research Manager
Bio Farma
INDONESIA



Vaibhav Dubey
Senior General Manager
Sun Pharmaceuticals
INDIA



Vipul Doshi
Chief Quality and Compliance Officer
Zydus Lifesciences
INDIA



Yagna Praveen
Asst Vice President, Head of Strategic Research
Pharmaniaga
MALAYSIA

Agenda At A Glance

CONFERENCE DAY 1 | 14TH OCTOBER 2026		CONFERENCE DAY 2 | 15TH OCTOBER 2026	
VACCINE WORLD ASIA CONGRESS 2026 South East Asia	BIOLOGICS WORLD SOUTH EAST ASIA 2026	VACCINE WORLD ASIA CONGRESS 2026 South East Asia	BIOLOGICS WORLD SOUTH EAST ASIA 2026
Opening Plenary Building Southeast Asia's Biologics & Vaccine Ecosystem		**mRNA, Viral Vector & Novel Platforms for Fast-Response Vaccines**	**Bioprocessing & Manufacturing Innovation in Southeast Asia**
MORNING TEA, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING			
Next-Generation Vaccine Discovery & Platform Technologies	**Therapeutic Biologics Market Growth & Commercial Opportunities in Southeast Asia**	**Vaccine Showcase** Emerging & Re-Emerging Infectious Diseases in Southeast Asia	**CDMO, Technology Transfer & Manufacturing Partnerships in Asia**
LUNCH, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING			
Clinical Trials & Regulatory Harmonization in SEA	**R&D, Clinical Development & Translational Science for Biologics**	**Vaccine Distribution & Cold Chain**	**Future Modalities** Next-Generation Cell & Advanced Biologics
AFTERNOON TEA, EXHIBITION VIEWING, POSTER PRESENTATIONS & 1-1 ATTENDEE NETWORKING			
Scaling Biomanufacturing Capacity & Technology Transfer Across SEA	**Clinical Adoption, Reimbursement & Market Access for Therapeutic Biologics**	**Leadership Panel** Can Southeast Asia Become a Global Biomanufacturing Powerhouse?	
END OF CONFERENCE			

Head of Production:
Lara Santiago · lara.santiago@imapac.com · +639176210686

Conference Producer:
Anusha Shirshyad · anusha.shirshyad@imapac.com · +6569645109

CONFERENCE AGENDA

Day 1

14 October 2026

Vaccine World Asia Congress 2026 | **Biologics World Asia Congress 2026**

8:50 — IMAPAC Opening Remarks

8:55 — **Chairman Welcome Remarks**



Butet Manurung
Managing Director, Jakarta Biopharmaceutical Industry (JBio)

Opening Plenary: Building Southeast Asia's Biologics & Vaccine Ecosystem

9:00 — **Opening Remarks**



Ms Wenny Indriasari
Director of Pharmaceutical and Medical Device Resilience, Ministry of Health

9:10 — **Panel Discussion: Building a Resilient Biologics & Vaccine Ecosystem in Southeast Asia: From Capacity to Capability**

- Bridging gaps across R&D, manufacturing, and supply chain to create a connected regional ecosystem
- Public-private partnerships: Aligning governments, industry, and academia to accelerate innovation
- Strengthening regional self-sufficiency vs. global dependency in vaccine and biologics production
- Talent, infrastructure, and policy: What's needed to position Southeast Asia as a global hub

MODERATOR



Dr. Mrunal Shetye
Chief of Health, UNICEF Indonesia Country Office

PANELISTS



Dr. Soleh Ayubi
Chief of Country Representative, PATH



Prasen Adya
Deputy Director, Serum Institute of India



Mr. Mohd Fadhil bin Razmi
Head of Cluster, Vaccine & Logistics, Malaysia Vaccine Project Office (MVPO), Ministry of Science, Technology & Innovation (MOSTI)



Meenu Batolar
Global Regulatory Affairs Asia Pacific Lead, CEPI

Vaccine World Asia Congress 2026 | Biologics World Asia Congress 2026

9:50

Accelerating the 100 Days Mission: Leveraging Platform Evidence and Innovative Safety Frameworks for Rapid Vaccine Development

- Harnessing platform technologies to accelerate vaccine development through the strategic use of prior CMC, non-clinical, and clinical data.
- Advancing regulatory preparedness by enabling reliance on platform knowledge, standardized approaches, and outbreak-responsive regulatory pathways
- Implementing risk-based safety frameworks that support Emergency Use Listing (EUL) while maintaining robust benefit-risk oversight
- Building evidence at the pace of pandemics through platform-specific safety surveillance, standardized AESI definitions, and real-world data generation



Meenu Batolar
Global Regulatory Affairs Asia Pacific Lead, CEPI

10:15

Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking

Vaccine World Asia Congress 2026

Next-Generation Vaccine Discovery & Platform Technologies

SESSION CHAIR



Prasen Adya
Deputy Director, Serum Institute of India

11:00

From Pathogen to Platform: Accelerating Vaccine Discovery in the Post-Pandemic Era

- What are the advantages of the RNA modality in infectious disease development and broader therapeutic areas?
- How can we achieve deep optimization of RNA technologies?
- In which potential areas might RNA technology outperform other modalities?



Dr. Wenshuo Zhou
Senior Director R&D & CEO Scientific Assistant, Abogen Biosciences

Biologics World Asia Congress 2026

Therapeutic Biologics Market Growth & Commercial Opportunities in Southeast Asia

11:00

Accelerating Biologics Innovation in Indonesia: From Research to Market Access

- Identifying gaps in the drug development process and potential solutions
- Exploring the end-to-end biologics development pipeline, from upstream research through commercialization and market access
- Examining the role of pentahelix collaboration in accelerating biologics innovation



Christian Karol Saputra
Head of Corporate Relation & Strategic Affair, Etana Biotechnologies

Vaccine World Asia Congress 2026

11:25

V2P – New generation Vaccines Delivery Solutions

- Vaccine packaging trends and future-ready delivery solutions
- Benefits of converting from Vial to prefilled for vaccine safety and efficiency
- Innovations in vaccine administration and immunization access
- How BD's integrated service and solution can support pharma companies for sustainable approaches to vaccine delivery and deployment



Sophie Lam
Regional Business Manager, BD Southeast Asia Biopharma System

11:45

Lunch, Exhibition Viewing & 1-1 Attendees Networking

Biologics World Asia Congress 2026

11:25

Tech Transfer in the Indonesian Context

- Design technology transfer for sustainable process control
- Integrate TKDN and regulatory requirements before design freeze
- Ensure localization strengthens the business case, not just the TKDN score



Nicolas Husser
Head of Operations, Kalbio Global Medika

11:50

Strategic Framework for Designing ADCs with a Better Therapeutic Window

- Building a quantitative model to explain discrepancies between the preclinical and clinical therapeutic windows of Topli payload ADCs
- Applying insights from the quantitative model to design new payloads for ADCs with an improved therapeutic window
- Expanding the application of quantitative models to enable the development of next-generation ADCs



Doo Young Jung
Chief Executive Officer, PinotBio

12:15

Lunch, Exhibition Viewing & 1-1 Attendees Networking

Vaccine World Asia Congress 2026

Clinical Trials & Regulatory Harmonization in SEA

1:30

The Future of Needle-Free Immunization: Advances in Intranasal and Mucosal Vaccines

- Advancing intranasal and mucosal vaccine platforms as alternatives to traditional injectable vaccines
- Understanding the potential of mucosal immunity for preventing infection and transmission
- Addressing R&D, clinical, regulatory, and manufacturing challenges in developing needle-free vaccines
- Exploring opportunities to improve vaccine accessibility, acceptance, and rapid deployment through next-generation delivery approaches



Dr. Seyed Reza Banihashemi
Director of R&D, Razi Vaccine & Serum Research Institute

Biologics World Asia Congress 2026

R&D, Clinical Development & Translational Science for Biologics

1:40

Clinical Development & Translational Science for Advanced Biologics

- Stages of translational science and the clinical development pathway
- Why advanced biologics translate differently: addressing the translation gap through quality by design (qbd)
- Key risks in clinical development & translational research: how translational teams can mitigate them



Chethan A J
Assistant Director - QA & RA, Center for Ocular Regeneration (CORE), Brien Holden Eye Research Center (BHERC)

Vaccine World Asia Congress 2026

1:55

Navigating Clinical Trials in Indonesia: Insights and Partnerships for Chinese and Local Stakeholders

- Practical experiences and lessons learned from conducting Phase 1/2 infants' polio vaccine trials in Indonesia.
- Key regulatory and operational considerations for non-Indonesian sponsors entering the Indonesian market.
- Bridging expectations: Understanding specific requirements from China to streamline cross-border collaborations.



Xiaoyuan Zhao
International Clinical Project Management Expert, R&D Division, CanSino Biologics Inc.

Biologics World Asia Congress 2026

2:05

Accelerating Biologics R&D: A Strategic Roadmap for Computational Engineering

- Navigating Multi-Parameter Optimization Trade-Offs: Biologics design requires balancing multiple properties, as optimizing target affinity can compromise critical attributes such as protein stability and selectivity
- Real-World Computational Case Studies: Demonstrating the application of physics-based modelling to large-scale mutagenesis, cross-reactivity screening, multi-parameter ideation, and addressing developability challenges
- Reducing Experimental Cycles and Development Risk: Predicting protein stability and binding energy to support candidate selection, minimize laboratory iterations, and accelerate the development of therapeutic biologics



Abhijit Kayal
Senior Scientist II, Schrodinger

Vaccine World Asia Congress 2026

2:20

Balancing speed & compliance in A Project Management Perspective

- Balancing accelerated vaccine development timelines with regulatory compliance and quality standards.
- Managing cross-functional teams, stakeholder alignment and project dependencies to minimise delays.
- Identifying project risks and bottlenecks across R&D, clinical trials and manufacturing.
- Applying agile project management approaches while maintaining documentation, traceability and regulatory readiness.



Indriana Permatasari
Project Manager, International Vaccine Institute (IVI)

2:45

Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking

Biologics World Asia Congress 2026

2:20

Reinventing the Quality Function: From Quality Assurance to Quality Intelligence

- Using AI to automate repetitive quality tasks and investigations
- Moving from periodic audits and inspection to predictive and continuous assurance
- Leveraging AI driven quality metrics to support faster, smarter decision making



Vipul Doshi
Chief Quality and Compliance Officer, Zydus Lifesciences

2:45

Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking

Vaccine World Asia Congress 2026

Scaling Biomanufacturing Capacity & Technology Transfer Across SEA

3:40

From Technology Transfer to Flexible Manufacturing: Building Scalable Vaccine Capacity in Southeast Asia

- Translating technology transfer into clear manufacturing, process and GMP requirements
- Designing for scale and flexibility, with modular manufacturing concepts and single-use technologies as key enablers
- Building future-ready manufacturing capacity that can adapt to different vaccine platforms, production volumes and evolving regional demand



Claire Chong
Technical application manager, Tofflon Science and Technology Group Co., Ltd.

Biologics World Asia Congress 2026

Clinical Adoption, Reimbursement & Market Access for Therapeutic Biologics

3:30

Generating Actionable Evidence: Medical Affairs as the Architect of Value in Biologics Access

- Addressing financial & access barriers to biologics in southeast asia
- Generating evidence to accelerate post launch access
- Building a unified medical affairs evidence strategy



Deepak Mukherjee
Country Medical Director, Roche

Vaccine World Asia Congress 2026

4:05

Winning the race to the market: The blueprint for flawless tech transfer

- Technical complexity and knowhow
- Hard and soft infrastructure
- Operational challenges
- Regulatory bottlenecks



Badarulhisam Abdul Rahman, PhD
Chief Scientific Officer, Pharmaniaga Berhad

Biologics World Asia Congress 2026

3:55

Panel Discussion: From Development to Adoption: Advancing Access to Innovative Biologics

- What are the key challenges in translating innovative biologics from clinical development into real-world clinical practice?
- How can clinical evidence, quality, and regulatory strategies better support clinical adoption and patient access?
- What can industry, healthcare providers, and policymakers do to build sustainable pathways for innovative biologics across Southeast Asia?

MODERATOR



Chethan A J
Assistant Director - QA & RA, Center for Ocular Regeneration (CORE), Brien Holden Eye Research Center (BHERC)

PANELISTS



Christian Karol Saputra
Head of Corporate Relation & Strategic Affair, Etana Biotechnologies



Deepak Mukherjee
Country Medical Director, Roche

Vaccine World Asia Congress 2026

4:30

Tech Transfer: Vaccines Accessibility and Affordability

- Accelerating technology transfer to strengthen local and regional vaccine manufacturing capacity
- Overcoming technical, regulatory and knowledge-transfer barriers to enable faster scale-up
- Reducing manufacturing costs to improve vaccine affordability and accessibility
- Building sustainable partnerships between vaccine developers, manufacturers and governments



Prasen Adya
Deputy Director, Serum Institute of India

4:55

Chairman Closing Remarks



Prasen Adya
Deputy Director, Serum Institute of India

5:00

END OF CONFERENCE - DAY 1

Biologics World Asia Congress 2026

4:35

Building Sustainable Market Access Pathways for Innovative Biologics in Asia



Reserved for Vaibhav Dubey
Senior General Manager, Sun Pharmaceuticals

5:00

Chairman Closing Remarks



Butet Manurung
Managing Director, Jakarta Biopharmaceutical Industry (JBio)

5:05

END OF CONFERENCE - DAY 1

CONFERENCE AGENDA

Day 2

15 October 2026

8:50 **IMAPAC Opening Remarks**

8:55 **Chairman Opening Remarks**



Indriana Permatasari
Project Manager, International Vaccine Institute (IVI)

VACCINE WORLD ASIA CONGRESS 2026 South East Asia — mRNA, Viral Vector & Novel Platforms for Fast-Response Vaccines

9:00 **mRNA Portfolios After COVID: From Breakthrough Breakthroughs to Sustainable Vaccine Platforms**

- How mRNA developers are transitioning from emergency-use success to scalable, multi-indication vaccine pipelines
- Advancing mRNA applications across infectious diseases, oncology, and personalized vaccines
- Comparing strengths, limitations, and hybrid strategies for rapid-response vaccine development
- Building resilient, cost-effective mRNA production and supply chains for global deployment



Dr. Indra Rudiansyah
Project Lead, mRNA Vaccine Programme, Bio Farma

8:55 **Chairman Opening Remarks**



Syifa Mutiara Hersista
Digital Tech Research Manager, Bio Farma

BIOLOGICS WORLD SOUTH EAST ASIA 2026 — Bioprocessing & Manufacturing Innovation in Southeast Asia

9:00 **Strengthening Regulatory Oversight & GMP Readiness for Advanced Biologics Manufacturing in Asia**

- Key regulatory challenges and opportunities in biologics manufacturing
- Enhancing GMP readiness and inspection capabilities for advanced modalities
- Lessons learned from regional regulatory convergence and PIC/S activities
- Strategies to strengthen manufacturing quality, compliance, and continuous improvement



Shanti Marlina Sibuea
Acting Director of Production Control of Drugs, Narcotics, Psychotropics, and Precursors, Indonesian National Agency of Drug and Food Control (Badan POM/BPOM)

9:25

Advancing Indonesia's Dengue Vaccine Innovation: Lessons from the Development of a Tetravalent mRNA Dengue Vaccine Prototype

- The journey behind developing Indonesia's tetravalent mRNA dengue vaccine prototype
- How academia, industry and government collaboration can accelerate homegrown vaccine R&D
- Opportunities and challenges in applying mRNA technology to dengue vaccine development
- Translating local vaccine innovation into clinical development, regulatory pathways and future access



M. Indra Lamora
Director – Anti Infectious Department, Etana Biotechnologies

9:25

Driving Acceleration in Insulin and GLP-1 Projects

- GLP-1 and biologics market trends shaping injectable drug delivery
- Patient-centric delivery solutions for self-injection
- De-risking and accelerating combination product development
- BD's technical, testing and regulatory support from concept to market



Sophie Lam
Regional Business Manager, BD Southeast Asia Biopharma System

9:40

AI for Biologics Innovation: From Intelligent Vaccine Design to Data-Driven Manufacturing

- AI Opportunities in Biologics Innovation
- Scaling AI from R&D to Manufacturing
- Overcoming Data, Validation & Regulatory Challenges



Syifa Mutiara Hersista
Digital Tech Research Manager, Bio Farma

9:50

Panel Discussion: Fast-Response Vaccines: Are Platform Technologies Ready for the Next Pandemic?

- Comparing speed, scalability, and flexibility of mRNA vs viral vectors
- Key bottlenecks in rapid design-to-deployment timelines
- Lessons from COVID-19: what worked, what didn't
- Building platform readiness for future outbreak scenarios

MODERATOR



Badarulhisam Abdul Rahman, PhD
Chief Scientific Officer, Pharmaniaga Berhad

PANELISTS



Dr. Indra Rudiansyah
Project Lead, mRNA Vaccine Programme, Bio Farma



M. Indra Lamora
Director – Anti Infectious Department, Etana Biotechnologies



Dr. Seyed Reza Banihashemi
Director of R&D, Razi Vaccine & Serum Research Institute



Dr. Martina Ochs
Programme Leader - RNA Programme, CEPI

10:05

Bioprocessing & Manufacturing Innovation in Southeast Asia

- Shift to Advanced Biologics and Vaccines: Transitioning from traditional generic drug manufacturing to high-value therapeutics, including monoclonal antibodies, biosimilars, and mRNA vaccine platforms
- Geographical Specialization and Stratification: Positioning regional markets as specialized R&D and CDMO hubs, leveraging strong institutional frameworks, abundant biomass, and large domestic markets to advance precision fermentation and vaccine self-sufficiency
- Adoption of Next-Generation Modular Technologies: Overcoming infrastructure limitations through flexible single-use bioreactors, continuous processing, and AI-driven process analytical technology (PAT) to achieve cost-effective manufacturing while maintaining international quality and compliance standards



Butet Manurung
Managing Director, Jakarta Biopharmaceutical Industry (JBio)

10:40 **Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking**

10:30 **Morning Tea Break, Exhibition Viewing & 1-1 Attendee Networking**

Vaccine Showcase: Emerging & Re-Emerging Infectious Diseases in South East Asia

11:20

RSV Prevention in Infants: Translating Clinical Evidence into Population-Level Protection

- Latest clinical and real-world evidence on RSV disease burden and vaccine effectiveness in infants and young children
- Understanding the impact of RSV prevention on hospitalizations, healthcare utilization, and long-term pediatric outcomes
- Identifying high-risk populations and strategies to maximize protection during the first years of life
- Translating evidence into national immunization policies and sustainable pediatric vaccination programs



Dr. Nicholas Lim
Medical Head, RSV Vaccines India & Southeast Asia MCO, Sanofi

CDMO, Technology Transfer & Manufacturing Partnerships in Asia

11:10

Building End-to-End CDMO Capabilities in Southeast Asia: From Tech Transfer to Commercial Supply

- Scaling from clinical to commercial manufacturing within regional CDMOs
- Infrastructure readiness: single-use systems, modular facilities, digitalization
- Ensuring consistency and comparability across sites
- Case studies of successful end-to-end CDMO partnerships



Lutfhi Zarkasyi
Director of Manufacturing, Kalbio Global Medika

11:45

Advancing Plasmodium vivax Vaccine R&D: Addressing an Emerging Infectious Disease Challenge in Southeast Asia

- Understanding the evolving P. vivax burden and its significance across Southeast Asia
- Addressing the scientific challenges of developing vaccines against P. vivax, including its complex life cycle
- Exploring innovative vaccine platforms, antigens and approaches to achieve durable protection
- Accelerating P. vivax vaccine candidates from research and clinical development toward regional access



Dr. Jetsumon Sattabongkot Prachumsri
Global Talent Researcher, Mahidol University

11:35

Accelerating GMP Readiness in SEA: Infrastructure, Quality Systems, and Compliance

- Establishing GMP-compliant facilities aligned with global regulatory standards
- Building QA/QC systems and inspection readiness (FDA, EMA, PIC/S)
- Workforce training and capability development for biologics manufacturing
- Common pitfalls in facility qualification and validation



Rakhmat Budi Yuwono
Quality Director, Etana Biotechnologies

12:00

Regulatory Updates on the Biologics Product Licensing Pathway in India

- Updates to the similar biologics' guidelines
- Digital transformation drive at CDSCO
- Legislative reforms on the horizon



Bobby George
Senior Vice President, Head Regulatory Affairs, Reliance Life Sciences

12:10 **Lunch, Exhibition Viewing & 1-1 Attendees Networking**

12:25 **Lunch, Exhibition Viewing & 1-1 Attendees Networking**

Vaccine Distribution & Cold Chain

SESSION CHAIR



Dr. Jetsumon Sattabongkot Prachumsri
Global Talent Researcher, Mahidol University

1:40

Scaling Vaccine Manufacturing in Southeast Asia: Strengthening Capacity, Digitalisation & Supply Reliability

- Scaling manufacturing capacity while maintaining GMP and product quality
- BCG vaccine manufacturing as a case study in managing biological complexity and process robustness
- Digitalisation and eBR to strengthen data integrity, process control and manufacturing efficiency
- Building reliable and resilient vaccine supply through operational excellence and technology transfer



Yuli Fitriyani Syoemantri
Head of BCG Vaccine Production Department, Bio Farma

Future Modalities: Next-Generation Cell & Advanced Biologics

1:40

Clinical Development of CAR-T Cell Therapy: Manufacturing, Formulation, Administration & Quality Control

- Key Considerations for CAR-T Cell Therapy Development
- Overview of the CAR-T Cell Manufacturing Process
- Phase I Clinical Trial of UWC19 in R/R B-NHL



Cheng Yi (Jerry) Kuo
Vice General Manager, UWELL Biopharma

2:05

Beyond Approval: Scaling Awareness, Access, and Sustainable Uptake of New Vaccines

- Improving public awareness and vaccine confidence
- Expanding access through innovative funding and reimbursement models
- Addressing affordability and health equity challenges
- Strengthening stakeholder collaboration to drive adoption
- Ensuring long-term sustainability of vaccination programs



Zainab Sadat
General Manager, Vaccines, Southeast Asia & India MCO, Sanofi

2:05

Applications of Regenerative Secretome Technology & Peptides in Functional Health

- Next-generation stem cell technology: cell-free, scalable, and cost-effective approaches
- The shift towards personalised early intervention
- Targeted applications in medical wellness



Kurt Wee
Chief Executive Officer, Celligenics

2:30

Reducing Vaccine Wastage: Inventory Management and Demand Forecasting in Cold Chain Systems

- Improving demand planning and stock allocation accuracy
- First-expiry-first-out (FEFO) and inventory tracking systems
- Minimizing overstocking and stockouts across regions
- Role of analytics and AI in supply chain optimization



Dr. Soleh Ayubi
Chief of Country Representative, PATH

2:30

The UCMSC Secretome: A Cell-Free Hydrogel for Tissue Regeneration in Chronic Wounds

- Dual Bioactivity: Anti-inflammatory and anti-fibrotic effects of the UCMSC secretome through macrophage polarization and reduction of TGF-β-induced α-SMA expression
- Clinical Efficacy: Evaluation of secretome hydrogel in chronic wound healing, including complete epithelialization within 5 days in a 64 cm^2 wound
- Advantages of Cell-Free Therapy: An off-the-shelf, serum- and antibiotic-free formulation with an 18-month shelf life, offering potential advantages in safety, scalability and regulatory development compared with live-cell therapies



Sandy Qlintang
President Director, Bifarma Adiluhung

2:55

Strategic Partnerships, Tech Transfer and Supply Chain Resilience

- Overcoming Market Size Constraints Through Win-Win Alliances: Learn how to position modest domestic market volumes as strategic regional opportunities to build partnerships with global players
- De-Risking Tech Transfer Through Rigorous Gap Remediation: Explore a systematic framework for CMC dossier audits, facility modifications, and milestone-gated technology transfer and licensing agreements (TTLMAs), aligned with ICH Q8–Q11 guidelines
- Strengthening Cold Chain and Upstream Sourcing Resilience: Gain practical insights into validating critical cold chain and supply logistics while securing uninterrupted supply amid global supply chain volatility



Yagna Praveen
Asst Vice President, Head of Strategic Research, Pharmaniaga

2:55 **Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking**

3:20 **Afternoon Tea Break, Exhibition Viewing & 1-1 Attendee Networking**

Leadership Panel: Can Southeast Asia Become a Global Biomanufacturing Powerhouse?

3:50

Leadership Panel: Can Southeast Asia Become a Global Vaccine & Biomanufacturing Powerhouse?

- What will it take for Southeast Asia to become a leading hub for vaccine and biologics manufacturing?
- How can governments and industry accelerate investments in talent, infrastructure, and advanced manufacturing capabilities?
- What role can regional collaboration play in strengthening supply chain resilience and reducing reliance on imports?

MODERATOR



Shanti Marlina Sibuea
Acting Director of Production Control of Drugs, Narcotics, Psychotropics, and Precursors, Indonesian National Agency of Drug and Food Control (Badan POM/BPOM)

PANELISTS



Dr. Neni Nurainy
Head of Translational Development of Life Science Product, Bio Farma



Butet Manurung
Managing Director, Jakarta Biopharmaceutical Industry (JBio)

4:30

Advancing Immunology, Innovation & Bioprocessing for Future Vaccines



Reserved for Dr. Seyed Reza Banihashemi
Director of R&D, Razi Vaccine & Serum Research Institute

4:55

Chairman Closing Remarks



Syifa Mutiara Hersista
Digital Tech Research Manager, Bio Farma

5:00

END OF CONFERENCE

Expected Audience Snapshot

60%
VACCINE & BIOLOGICS BIOPHARMA

80%
DECISION MAKERS

BY PROFILE

Vaccine & Biologics Biopharma (SEA)	40%
Big Pharma / International Biopharma	15%
CMOs/CDMOs/CROs	15%
Technology & Service Providers	15%
Academic & Research Institutes	8%
Government & Regulators	7%

BY JOB TITLE

VPs/Heads of R&D, Discovery & Process Development	25%
CEO/CSO/COO/CTOs	15%
Heads of Manufacturing, Bioprocessing, QA, CMC & Analytics	15%
VPs/Heads of Clinical Trials & Logistics	12%
USP & DSP Specialists & Researchers	11%
Business Development & Marketing	12%
Professors/Scientists/Academics	5%
Heads of Fill & Finish and Packaging	5%




BY GEOGRAPHY

- 35% Singapore, Thailand, Malaysia, Laos & Vietnam
- 25% Indonesia
- 25% China, Taiwan, Korea & Japan
- 10% Australia, India & Hong Kong
- 5% USA & Europe

Exhibition Floorplan

Sheraton Grand Jakarta Gandaria City Hotel, Jakarta. 14 - 15 October 2026.

6 sqm stand (3 m x 2 m) 4 sqm stand (2 m x 2 m) 1 sqm stand (1 m x 1 m)



EXHIBITOR

- 08 Air Dynamics
- 13 Cytiva
- 9a Marken
- 9d Schrodinger
- 05 Becton Dickinson
- 03 Dou Yee Enterprises
- 9b Optima
- 12 Waters
- 06 Becton Dickinson
- 04 Haier Biomedical
- 02 Pfanstiehl
- 11 BioMed Global
- 9c Inmark Lifescience
- 07 Regenic

Floorplan is subject to change.

Exhibition Floorplan 3D VIEW

Sheraton Grand Jakarta Gandaria City Hotel, Jakarta. 14 - 15 October 2026.

6 sqm stand (3 m x 2 m) 4 sqm stand (2 m x 2 m) 1 sqm stand (1 m x 1 m)



EXHIBITOR

08	Air Dynamics	05	Becton Dickinson	06	Becton Dickinson	11	BioMed Global
13	Cytiva	03	Dou Yee Enterprises	04	Haier Biomedical	9c	Inmark Lifescience
9a	Marken	9b	Optima	02	Pfanstiehl	07	Regenic
9d	Schrodinger	12	Waters				

Floorplan is subject to change.

Who Should Sponsor?

- COLD CHAIN & TEMPERATURE CONTROLLED TRANSPORT
- PACKAGING AUTOMATION
- PACKAGING SOLUTIONS/ SEALING SOLUTIONS
- VACCINE DELIVERY & FORMULATION TECHNOLOGY PROVIDERS
- QA/QC TESTING
- CDMO / CMO (CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS)
- CELL LINE & VACCINE PLATFORM TECHNOLOGY PROVIDERS
- VACCINE PRODUCTION AND DEVELOPMENT
- FILL AND FINISH SERVICE PROVIDERS
- BIOPROCESSING & MANUFACTURING EQUIPMENT PROVIDERS
- ANALYTICAL TESTING & QC LABS
- PROCESS DEVELOPMENT & CDMOS
- CLINICAL RESEARCH ORGANIZATIONS (CROS)
- PASSIVE PACKAGING SUPPLIERS
- LOGISTICS COMPANIES
- PROCESS DEVELOPMENT & CDMOS
- RAW MATERIALS & REAGENTS SUPPLIERS
- REGULATORY AFFAIRS & CONSULTING

Why Sponsor This Event?

Thought Leadership

Present Your Expertise to the Biopharma Industry's Key Stakeholders through a Variety of Available Speaking Packages.

Host a Panel Discussion

Moderate a panel discussion including one representative from your company with 3 representatives from the end user side to share views on a current industry topic

Duration: 45 minutes

Showcase Your Solutions to Educate the Market

Join in for dedicated CMO & CRO Showcases

Branding

Emphasize on your Message by Marketing and Promoting Alongside the Event

Networking & Lead Generation

Gain Exclusive Access to Contacts of High Profile Attendees through Intimate Networking Opportunities

Business Development Manager:
Nathan Grace Niño · nathan.grace@imapac.com · +6569836134

Our Past Partners



Business Development Manager:
Nathan Grace Niño · nathan.grace@imapac.com · +6569836134

MARK YOUR CALENDAR

Save the Date

14 - 15 OCT 2026

Sheraton Grand Jakarta Gandaria City Hotel

VWSEA & BWSEA 2026 Brochure

ALL IMAPAC EVENTS

Explore Our Full Event Calendar

Discover all upcoming and future IMAPAC events across Asia-Pacific: biopharmaceutical conferences, summits and exhibitions for the year ahead.

→

OR ADD THIS EVENT TO YOUR CALENDAR

Google Calendar
One-click add to Gmail →

Outlook Calendar
Add to Microsoft Outlook →

Scan to Register

Open camera, point at code, instant registration access.

Or click the QR to open registration directly.

Registration Form

CATEGORY	EARLY BIRD (By 15 May 2026)	REGISTRATION (By 17 July 2026)	STANDARD (By 18 September 2026)	FINAL CALL
BIOPHARMA, ACADEMIC & RESEARCH — BASED IN ASIA (APAC)				
2-Day Conference Pass **Job Profiles:** Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,495	SGD 1,695	SGD 1,895	SGD 2,095
BIOPHARMA, ACADEMIC & RESEARCH — BASED OUTSIDE OF ASIA				
2-Day Conference Pass **Job Profiles:** Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,995	SGD 2,195	SGD 2,395	SGD 2,595
BIG PHARMA, SOLUTION / SERVICE / TECHNOLOGY PROVIDERS & CDMO/CMO				
2-Day Conference Pass Business Development, Marketing & Sales profiles	SGD 2,995	SGD 3,195	SGD 3,395	SGD 3,595

BRING YOUR TEAM - Group Discount

Asia & International Biopharma

☐ Buy 2, Get 3 passes
☐ Buy 3, Get 5 passes

Limited to professionals in the "BUYER" profile working in Process Development, R&D, QC & Assurance, Manufacturing Heads, Engineering, Upstream, Downstream or Analytical in Big Pharmas, International / Asian Biopharmas, and Academic & Research Institutes.

INNER CIRCLE Speaker referrals and professionals working in the same organisation as our speakers are entitled to a 15% discount.

- Access to all conference proceedings for up to 30 days.
- Site Tour Package is applicable only with the purchase of a conference pass.

Standard Package Group Discount

3 Delegates Save 10% ☐ 5 Delegates Save 20% ☐ 6+ Delegates Save 25% ☐

EVENT VENUE



Sheraton Grand Jakarta Gandaria City Hotel, Indonesia

14 - 15 October 2026

3 EASY WAYS TO REGISTER

Online
https://www.imapac.com/events/vaccine-world-asia-congress-2026---south-east-asia

Telephone
+65 6983 6140 (SG) / +44 161 552 8507 (UK)

Mail
Cheque payable to IMAPAC Pte Ltd,
36 Robinson Road, #02-01
068877
Singapore

Cheque payable to IMAPAC UK Ltd,
77 Farringdon Road, Farringdon, London
EC1M 3JU
United Kingdom

YOUR DETAILS

Name _____
Job Title _____ Organization _____
Address _____
Postcode _____ Country _____
Tel _____ Fax _____
Email _____
Your primary business _____
Authorising Manager _____ Authorising manager signature _____

PAYMENT DETAILS

Payment is due immediately upon receipt of this registration form if you pay by credit card or 3 working days after your receipt of payment notification. Non-credit card payment will incur an additional US$100 (Bank handling fee)

I want to pay: ☐ Credit Card ☐ Bank Transfer ☐ Cheque

Offline credit card: ☐ Visa ☐ MasterCard ☐ American Express

Online credit card payment: Please register at https://www.imapac.com/events/vaccine-world-asia-congress-2026---south-east-asia#register

Name on Card _____ Card Number _____
Expiry Date (MM/YY) _____ CVC Code _____ Signature _____

TERMS & CONDITIONS

Payment & Registration
Full payment is due upon registration if you pay by credit card, or 3 working days after receipt of invoice. Registration will not be confirmed until full payment has been received.
Unpaid registration will be billed 50% of the registration fee if you do not attend the event. A copy of the conference documentation will be mailed to you. Staff at the event will request a credit card guarantee for delegates without proof of payment.

Ticket Classification
All registrations are reviewed to ensure correct classification. Biopharma tickets are reserved for professionals employed by pharmaceutical or biopharmaceutical companies that develop, own or commercialise therapeutic drug products. Service, Solution and Technology Provider tickets apply to organisations offering services, platforms, technologies, equipment, consultancy or manufacturing services to the industry (including CROs, CDMOs, vendors, consultants and suppliers).
Purchasing an incorrect ticket does not guarantee entry. IMAPAC retains full discretion to deny access, reclassify registrations and issue an invoice for the price difference. Incorrect ticket purchases under an inappropriate classification are not eligible for refunds under any circumstances.

Cancellation & Substitution Policy
Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference, attendees will receive a full credit note towards a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee.
A substitution from the same organisation can be made at any time in writing at no extra charge. In the event that IMAPAC cancels a conference, payments received at the cancellation date will be credited towards attendance at a future conference, or in the event of postponement by IMAPAC, towards the rescheduled date. Credit notes remain valid for twelve months.

Changes to Conference & Agenda
IMAPAC reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers for an event. IMAPAC is not responsible for any loss or damage as a result of substitution, alteration, postponement or cancellation of an event due to causes beyond its control including, without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. In the event that a conference is cancelled, IMAPAC is not liable for any costs incurred by delegates in connection with their attendance. Changes to the agenda will be updated on our website as soon as possible.

Data Protection
The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to reputable third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: data@imapac.com.

E: ana.laxamana@imapac.com | nathan.grace@imapac.com C: +65 6983 6132 | +65 6983 6134

Registration Form

CATEGORY	EARLY BIRD (By 15 May 2026)	REGISTRATION (By 17 July 2026)	STANDARD (By 18 September 2026)	FINAL CALL
BIOPHARMA, ACADEMIC & RESEARCH — BASED IN ASIA (APAC)				
2-Day Conference Pass **Job Profiles:** Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,495	SGD 1,695	SGD 1,895	SGD 2,095
BIOPHARMA, ACADEMIC & RESEARCH — BASED OUTSIDE OF ASIA				
2-Day Conference Pass **Job Profiles:** Manufacturing, Bioprocessing, Production, USP, DSP, Operations, Site Heads, Drug Substance and Product Manufacturing, Process Development, Quality, Analytics and other related technical designations	SGD 1,995	SGD 2,195	SGD 2,395	SGD 2,595
BIG PHARMA, SOLUTION / SERVICE / TECHNOLOGY PROVIDERS & CDMO/CMO				
2-Day Conference Pass Business Development, Marketing & Sales profiles	SGD 2,995	SGD 3,195	SGD 3,395	SGD 3,595

BRING YOUR TEAM - Group Discount

Asia & International Biopharma

☐ Buy 2, Get 3 passes
☐ Buy 3, Get 5 passes

Limited to professionals in the "BUYER" profile working in Process Development, R&D, QC & Assurance, Manufacturing Heads, Engineering, Upstream, Downstream or Analytical in Big Pharmas, International / Asian Biopharmas, and Academic & Research Institutes.

INNER CIRCLE Speaker referrals and professionals working in the same organisation as our speakers are entitled to a 15% discount.

- Access to all conference proceedings for up to 30 days.
- Site Tour Package is applicable only with the purchase of a conference pass.

Standard Package Group Discount

3 Delegates Save 10% ☐ 5 Delegates Save 20% ☐ 6+ Delegates Save 25% ☐

EVENT VENUE



Sheraton Grand Jakarta Gandaria City Hotel, Indonesia

14 - 15 October 2026

3 EASY WAYS TO REGISTER

Online
https://www.imapac.com/events/biologics-world-south-east-asia-2026#register

Telephone
+65 6983 6140 (SG) / +44 161 552 8507 (UK)

Mail
Cheque payable to IMAPAC Pte Ltd,
36 Robinson Road, #02-01
068877
Singapore

Cheque payable to IMAPAC UK Ltd,
77 Farringdon Road, Farringdon, London
EC1M 3JU
United Kingdom

YOUR DETAILS

Name _____
Job Title _____ Organization _____
Address _____
Postcode _____ Country _____
Tel _____ Fax _____
Email _____
Your primary business _____
Authorising Manager _____ Authorising manager signature _____

PAYMENT DETAILS

Payment is due immediately upon receipt of this registration form if you pay by credit card or 3 working days after your receipt of payment notification. Non-credit card payment will incur an additional US$100 (Bank handling fee)

I want to pay: ☐ Credit Card ☐ Bank Transfer ☐ Cheque

Offline credit card: ☐ Visa ☐ MasterCard ☐ American Express

Online credit card payment: Please register at https://www.imapac.com/events/biologics-world-south-east-asia-2026#register

Name on Card _____ Card Number _____
Expiry Date (MM/YY) _____ CVC Code _____ Signature _____

TERMS & CONDITIONS

Payment & Registration
Full payment is due upon registration if you pay by credit card, or 3 working days after receipt of invoice. Registration will not be confirmed until full payment has been received.
Unpaid registration will be billed 50% of the registration fee if you do not attend the event. A copy of the conference documentation will be mailed to you. Staff at the event will request a credit card guarantee for delegates without proof of payment.

Ticket Classification
All registrations are reviewed to ensure correct classification. Biopharma tickets are reserved for professionals employed by pharmaceutical or biopharmaceutical companies that develop, own or commercialise therapeutic drug products. Service, Solution and Technology Provider tickets apply to organisations offering services, platforms, technologies, equipment, consultancy or manufacturing services to the industry (including CROs, CDMOs, vendors, consultants and suppliers).
Purchasing an incorrect ticket does not guarantee entry. IMAPAC retains full discretion to deny access, reclassify registrations and issue an invoice for the price difference. Incorrect ticket purchases under an inappropriate classification are not eligible for refunds under any circumstances.

Cancellation & Substitution Policy
Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference, attendees will receive a full credit note towards a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee.
A substitution from the same organisation can be made at any time in writing at no extra charge. In the event that IMAPAC cancels a conference, payments received at the cancellation date will be credited towards attendance at a future conference, or in the event of postponement by IMAPAC, towards the rescheduled date. Credit notes remain valid for twelve months.

Changes to Conference & Agenda
IMAPAC reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers for an event. IMAPAC is not responsible for any loss or damage as a result of substitution, alteration, postponement or cancellation of an event due to causes beyond its control including, without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities. In the event that a conference is cancelled, IMAPAC is not liable for any costs incurred by delegates in connection with their attendance. Changes to the agenda will be updated on our website as soon as possible.

Data Protection
The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to reputable third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: data@imapac.com.

E: ana.laxamana@imapac.com | nathan.grace@imapac.com C: +65 6983 6132 | +65 6983 6134

A VARIETY OF PRODUCTS TO CATER TO GLOBAL BIOPHARMACEUTICAL INDUSTRY'S MARKET INTELLIGENCE AND BUSINESS CONNECTIONS NEEDS.

01 B2B EVENTS

Thought-leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events.

Create an engaging experience for your audiences, explore our B2B Events Solutions.

02 360 MARKETING SOLUTIONS

Expand your reach and influence! Be it with customized events, digital marketing solutions, content creation or thought-leadership.

Tap into our pool of audience that spans across various sub-sectors and regions critical in the burgeoning APAC biopharmaceutical sector.

03 DASHBOARDS

A quick-view analytics tool to power your decisions. Access region or country-specific data to uncover pipeline information, product focus.

Customize the dashboard based on your needs. Drill down to the data you need using custom views.

04 CUSTOM RESEARCH

Based on your objectives and budget, you can customize a package to one that best meets your intelligence needs. This allows you to maximize your ROI without spending on items that are not in line with your strategies.

With access to a database of 60,000+ life science professionals. We conduct research with a highly-qualified audience.

05 REPORTS

Discover in-depth market information of the growing biopharmaceutical sector.

Learn More →

IMAPAC
IMAGINE YOUR IMPACT

HELPING THE GLOBAL BIOPHARMACEUTICAL INDUSTRY

Generate Tangible Growth

IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. We help companies expand their influence, make data driven decisions through our industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking. At the core of IMAPAC is our mission to help biopharmaceutical businesses globally generate tangible growth. At the same time, our heart lies in giving back to society. We empower the next generation by equipping underprivileged children with an education.

WEBSITE
imapac.com

EMAIL
info@imapac.com

IMAPAC PTE LTD
36 Robinson Road, #02-01
Singapore 068877
+65 6983 6140

IMAPAC UK LTD
77 Farringdon Road, Farringdon
London EC1M 3JU, United Kingdom
+44 161 552 8507

CONNECT WITH US

LINKEDIN
@imapac

X
@imapac

FACEBOOK
ImapacPteLtd